𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Benefits and costs of newer drugs: an update

✍ Scribed by Frank R. Lichtenberg


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
137 KB
Volume
28
Category
Article
ISSN
0143-6570

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

In previous work, we found strong evidence to support the hypothesis that the replacement of older drugs by new drugs resulted in reductions in total medical expenditures. In this study, we update and extend our previous study of the effect of drug age—years since FDA approval—on total medical expenditure, in several respects: (1) the unit of analysis is a medical condition, rather than a prescription; (2) the sample is much larger, including data for 3 years, rather than 1 year; (3) we obtain estimates for the Medicare population as well as for the entire population; and (4) within the Medicare population, we examine the effect of drug age on Medicare expenditure as well as on expenditure by all payers.

The estimates indicate that, in the entire population, a reduction in the age of drugs utilized reduces non‐drug expenditure 7.2 times as much as it increases drug expenditure. For example, reducing the mean age of drugs used to treat a condition from 15 years to 5.5 years is estimated to increase prescription drug spending by $18 but reduce other medical spending by $129, yielding a $111 net reduction in total health spending. Most of the savings are due to reductions in hospital expenditure ($80) and in physician office‐visit expenditures ($24).

In the Medicare population, a reduction in the age of drugs utilized reduces non‐drug expenditure by all payers (i.e. Medicare and various forms of Medicare supplemental insurance, Medicare for dually eligible individuals and Medicare beneficiaries' out of pocket payments) 8.3 times as much as it increases drug expenditure; it reduces Medicare non‐drug expenditure 6.0 times as much as it increases drug expenditure. About two‐thirds of the non‐drug Medicare cost reduction is due to reduced hospital costs. The remaining third is approximately evenly divided between reduced Medicare home health care cost and reduced Medicare office‐visit cost.

We also show that Medicare enrollees with private prescription drug coverage tend to use newer drugs than those without such coverage: the mean age of drugs used by Medicare enrollees with private Rx insurance is about 9% lower than the mean age of drugs used by Medicare enrollees without either private or public Rx insurance. Copyright © 2007 John Wiley & Sons, Ltd.


📜 SIMILAR VOLUMES


Cost benefits of substance abuse treatme
✍ Harold D. Holder 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

Background and Methods: The treatment of substance abuse is an important health service available in all industrialized countries throughout the world. Cost of treatment and its benefit or economic value is an important policy issue. Reduction in health care cost is one alternative way to measure be

The effect of newer drugs on health spen
✍ Abdülkadi̇r Ci̇van; Bülent Köksal 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

## Abstract We analyze the influence of technological progress on pharmaceuticals on rising health expenditures using US State level panel data. Improvements in medical technology are believed to be partly responsible for rapidly rising health expenditures. Even if the technological progress in med

The costs and benefits of phased retirem
✍ David W. Leslie 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 56 KB

## Abstract Individuals who retire have widely varying needs and differ also in their preparedness for their new conditions.